Fig. 3
Separate and simultaneous treatment of AA and LA on non-SRCC cells (GPM-1), patient-derived gastric origin SRCC (GPM-2), gastric-origin SRCCs (HSC-39 and KATO-3) and human pancreatic (MIA PaCa-2) and ovarian (SKOV-3) lines. A Inhibition curves of AA after 16-h incubation. B Inhibition curves of LA after an incubation of 16 h. C 16-h inhibition curves of AA & LA (simultaneously) on various cells. D IC50 of all cells after AA and AA&LA treatments. E Viability of cells after incubations with AA, LA or combinations, respectively. Cells after treatments were stained with calcein and scanned on a Celigo imaging cytometer